XML 39 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value of Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2025
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

 

 

 

 

 

 

September 30, 2025

 

 

 

Total Fair

 

 

 

 

 

 

 

 

 

 

(in thousands)

 

Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

108,576

 

 

$

108,576

 

 

$

 

 

$

 

Investment securities

 

 

45,480

 

 

 

45,480

 

 

 

 

 

 

 

Total assets

 

$

154,056

 

 

$

154,056

 

 

$

 

 

$

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Deferred compensation plan liabilities

 

$

942

 

 

$

942

 

 

$

 

 

$

 

Contingent consideration liabilities

 

 

97,824

 

 

 

 

 

 

 

 

 

97,824

 

Total liabilities

 

$

98,766

 

 

$

942

 

 

$

 

 

$

97,824

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2024

 

 

 

Total Fair

 

 

 

 

 

 

 

 

 

 

(in thousands)

 

Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

682,209

 

 

$

682,209

 

 

$

 

 

$

 

Investment securities

 

 

39,489

 

 

 

39,489

 

 

 

 

 

 

 

Total assets

 

$

721,698

 

 

$

721,698

 

 

$

 

 

$

 

Schedule of Company's Contingent Consideration Liabilities

The recurring Level 3 fair value measurements of the Company's contingent consideration liabilities include the following significant unobservable inputs (in thousands, except percent data):

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

Contingent Consideration Liability

 

September 30,
2025

 

 

Valuation Technique

 

Unobservable Inputs

 

Range

 

Weighted Average

Development and commercialization milestones

 

 

40,965

 

 

Discounted cash flow

 

Payment discount rate

 

8.1% - 13.3%

 

8.3%

 

 

 

 

 

 

 

Probability of payment

 

0.0% - 100.0%

 

87.3%

 

 

 

 

 

 

 

Range of expected payment dates

 

2026 - 2037

 

N/A

Sales milestones

 

 

30,059

 

 

Scenario analysis

 

Revenue volatility

 

37.0% - 48.0%

 

46.9%

 

 

 

 

 

 

 

Revenue discount rate

 

9.4% - 19.3%

 

17.8%

Assumed contingent consideration from Piramal SPA

 

 

26,800

 

 

Scenario analysis

 

EBITDA volatility

 

60.0%

 

60.0%

 

 

 

 

 

 

 

EBITDA discount rate

 

21.4% - 22.0%

 

21.4%

Total contingent consideration liabilities

 

$

97,824

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Schedule of contingent consideration measured at fair value

The following table reflects the activity for the Company’s contingent consideration measured at fair value using Level 3 inputs for the nine months ended September 30, 2025:

 

 

Level 3

 

 

 

Accrued Contingent

 

(in thousands)

 

Consideration

 

Balance December 31, 2024

 

$

 

Evergreen acquisition

 

 

43,042

 

Life Molecular acquisition

 

 

53,800

 

Changes in fair value included in net income

 

 

982

 

Balance September 30, 2025

 

$

97,824